NCT07488897

RIG 101 Trial in Healthy Adults and Adults With Asthma

A Two-part Randomized, Double-blind Placebo Controlled Trial to Assess the Safety and Tolerability of Single and Repeat Ascending Intranasal Doses of RIG-101 in Healthy Participants Followed by Repeat Daily Administration in Adult Participants With Asthma [Part A] Followed by a Randomized Double-blind Placebo Controlled Part to Assess the Efficacy and Safety of RIG-101 in Adult Participants With Asthma Before and After Viral Challenge With Human Rhinovirus RV-A16 [Part B].

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 82 (estimated)
• Sponsor: RIGImmune Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Nested Phase 1-2 Trial of RIG-101 in Healthy and Asthmatic Participants Assessing Safety, Tolerability and Viral Challenge Efficacy

Conditions

• Healthy Adult Participants
• Asthma Exacerbation
• Safety and Efficacy

Interventions

Type	Name	Description
DRUG	RIG-101	Single, and repeat escalating intranasal administrations of RIG-101
OTHER	Placebo	Single and repeat Intranasal administrations

Timeline

• Start date: 2026-02-09
• Primary completion: 2027-02-01
• Completion: 2027-02-01
• First posted: 2026-03-23
• Last updated: 2026-03-23

Locations

2 sites across 1 country: United Kingdom